Investor briefing-AD-214 top line single dose safety results
Filed with ASX · · 35 pages · English
MELBOURNE Australia, 10 March 2021: AdAlta Limited (ASX:1AD), a clinical stage biopharmaceutical discovery and development company using i-body technology to address challenging drug targets is hosting an investor briefing at 1100 AEDT today to discuss top line results from Part A of its Phase I clinical program studying single ascending doses (SAD) of lead asset AD-214 in healthy volunteers (HVs)
In the deck
Earlier from AdAlta
- Appendix 4D and Interim Financial Report
- FDA Orphan Drug Designation for AD-214
- Phase I HV extension to explore encouraging results
- AGM Presentation
- AusBiotech presentation including Phase I status update
Later from AdAlta
- Mutiple Dose Part Of Ad-214 Phase I Trial Commenced
- AdAlta granted Japanese patent for AD-214
- GE Healthcare collaboration advances to next stage
- R&D Tax Incentive Facility
- AdAlta secures AD-214 resupply
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta